What is a stock summary page? Click here for an overview.
Business Description
Pharming Group
NAICS : 325414
SIC : 2836
ISIN : NL0010391025
Compare
Compare
Traded in other countries / regions
PHARM.Netherlands0QCO.UKPHGUF.USAPHGN.Germany IPO Date
2008-11-14Description
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.5 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.51 | |||||
| Debt-to-EBITDA | 7.24 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.14 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.9 | |||||
| 3-Year EBITDA Growth Rate | -31.4 | |||||
| 3-Year Book Growth Rate | 5.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.51 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 8.71 | |||||
| 9-Day RSI | 41.7 | |||||
| 14-Day RSI | 59.09 | |||||
| 3-1 Month Momentum % | -2.35 | |||||
| 6-1 Month Momentum % | 23.02 | |||||
| 12-1 Month Momentum % | -18.58 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.77 | |||||
| Quick Ratio | 3.02 | |||||
| Cash Ratio | 2.27 | |||||
| Days Inventory | 593.39 | |||||
| Days Sales Outstanding | 52.56 | |||||
| Days Payable | 488.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.6 | |||||
| Shareholder Yield % | 6.86 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.06 | |||||
| Operating Margin % | -1.08 | |||||
| Net Margin % | -3.91 | |||||
| FCF Margin % | -0.86 | |||||
| ROE % | -5.34 | |||||
| ROA % | -2.72 | |||||
| ROIC % | -2.32 | |||||
| 3-Year ROIIC % | -119.4 | |||||
| ROC (Joel Greenblatt) % | -0.78 | |||||
| ROCE % | -0.15 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 44.87 | |||||
| PS Ratio | 2.04 | |||||
| PB Ratio | 2.37 | |||||
| Price-to-Tangible-Book | 3.16 | |||||
| Price-to-Operating-Cash-Flow | 736 | |||||
| EV-to-EBIT | -1023.24 | |||||
| EV-to-Forward-EBIT | -14.5 | |||||
| EV-to-EBITDA | 31.07 | |||||
| EV-to-Forward-EBITDA | -17.58 | |||||
| EV-to-Revenue | 1.67 | |||||
| EV-to-Forward-Revenue | 1.51 | |||||
| EV-to-FCF | -192.42 | |||||
| Price-to-GF-Value | 0.62 | |||||
| Price-to-Projected-FCF | 2.08 | |||||
| Price-to-Median-PS-Value | 0.47 | |||||
| Price-to-Net-Current-Asset-Value | 5.33 | |||||
| Earnings Yield (Greenblatt) % | -0.1 | |||||
| FCF Yield % | -0.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharming Group Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 275.912 | ||
| EPS (TTM) (€) | -0.016 | ||
| Beta | -0.02 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.17 | ||
| Volatility % | 40.31 | ||
| 14-Day RSI | 59.09 | ||
| 14-Day ATR (€) | 0.000163 | ||
| 20-Day SMA (€) | 0.8525 | ||
| 12-1 Month Momentum % | -18.58 | ||
| 52-Week Range (€) | 0.693 - 1.047 | ||
| Shares Outstanding (Mil) | 683.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharming Group Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharming Group Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pharming Group Frequently Asked Questions
What is Pharming Group(CHIX:PHARMa)'s stock price today?
The current price of CHIX:PHARMa is €0.85. The 52 week high of CHIX:PHARMa is €1.05 and 52 week low is €0.69.
When is next earnings date of Pharming Group(CHIX:PHARMa)?
The next earnings date of Pharming Group(CHIX:PHARMa) is 2025-05-08 Est..
Does Pharming Group(CHIX:PHARMa) pay dividends? If so, how much?
Pharming Group(CHIX:PHARMa) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers